Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa

INTRODUCTION: A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and Drug Administration approved without extensive study of clinical effectiveness, due to an overwhelming demand for FXa inhibitor reversal. In this study, we aimed to describe patient selection, clinical effect...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thromb Haemost
Autors principals: Nederpelt, Charlie J., Naar, Leon, Sylvester, Katelyn W., Barra, Megan E., Roberts, Russel J., Velmahos, George C., Kaafarani, Haytham M. A., Rosenthal, Martin G., King, David R.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
HAEMOSTASIS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7589264/
https://ncbi.nlm.nih.gov/pubmed/32738161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.15031
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars